以下文章来源于定焦One ，作者定焦One团队 定焦One . 深度影响创新。 来源|定焦One 作者 | 张潇潇 编辑 | 魏佳 当观众沉迷于短剧中"霸道总裁爱上我"的剧情 无法自拔时 ，现实生活中的"霸总们"也正在对品牌定制短剧一边上头、一边下单。 在长剧和电影市场疲软之时，短剧以井喷之势，成为文娱产业的最大风口。数据显示，短剧的内容供给数量，从2022年备案的336部激增到2024年 全网上线超 3.64 万部。其市场规模从2021年的3.68亿，快速扩张到2024年的504亿，首次超过电影票房大盘。多个机构预测，2027年短剧将迎来 千亿市场。 短剧的火，不只在内容端，更在于其商业化潜力。在流量焦虑的当下，品牌方比短剧女主更渴望借着短剧 "逆袭重生"。 仅2025年 前四个月 ，新上 线品牌短剧就有153部。品类上，除美妆、食饮外，还包括电商、文旅、金融等行业，近半数品牌为首次入局。 但热闹背后，很多品牌商家也有困惑。一方面，大量品牌定制短剧涌入市场，营销费用和制作成本水涨船高，流量边际效益却在递减。另一方面，当 短剧成为品牌营销的大势所趋，不跟风又会有强烈的掉队之感。 不做怕掉队，做了怕白费。品牌短 ...

瑞财经 严明会6月30日，深圳市维琪科技股份有限公司（以下简称：维琪科技）北交所IPO获受理，保 荐机构国信证券，保荐代表人楼瑜、郑桂斌，会计师事务所为致同会计师事务所。 截至招股说明书签署日，公司拥有16个经国家药监局批准备案的化妆品新原料， 其中包括7个创新新原 料，公司新原料备案获批数量位居第一，创新新原料备案获批数量位居第一。维琪科技已进入丸美、宝 洁等国内外知名品牌供应链体系。 丁文锋、赖燕敏夫妻为维琪科技共同实际控制人，二人合计控制公司 62.1%的股权。 董事长兼总经理丁文锋直接持有57.28%的股份，并担任公司员工持股平台维聚康的执行事务合伙人， 通过维聚康间接控制公司1.27%的股份，丁文锋直接和间接合计控制公司 58.55%的股份，为公司控股股 东。 丁文锋，48岁，博士研究生学历，2000年9月至2001年1月就职于深圳市万乐药业有限公司，担任研发人 员；2001年2月至2014年3月就职于康哲医药研究(深圳)有限公司，从事新药研发；2014 年至今就职于维 琪科技，现任公司董事长兼总经理。 | 品牌商 | 产品 | 使用公司新原料 | | --- | --- | --- | | 丸美 ...

2 0 2 5年7月，丸美再一次站在眼部护理赛道的聚光灯下。 第1 2届"眼霜节"如期而至，这一专属品牌的大IP延续了与艺术跨界合作的传统，并迎来一个里 程碑时刻：中国香料香精化妆品工业协会理事长颜江瑛亲临现场，为丸美授予"国货眼部护理 第一品牌"奖牌。 在消费越来越理性、护肤赛道日趋细分的当下，眼部护理这条技术密集、信任门槛极高的细分 战场，一直是品牌们难以啃下的一块骨头。 但有丸美却偏偏在这条窄路上跑出了主道，接连拿下连续三年眼部护理销售额第一，国货眼部 护理第一品牌几个含金量极高的头衔，并用一个做了1 2年"眼霜节" IP，把眼霜品类做到有节 日、有粉丝、有文化、还能年年翻红。 如果只看"卖得好"，那只是销售结果。但如果换个角度，从科研、产品、文化三个维度来看， 就会发现，丸美其实早就不是"爆品玩家"，而是用稳扎稳打的系统力，定义了什么叫"眼部护 理国货标杆"。 2 0 2 5年7月，第1 2届"眼霜节"如期而至，这一专属丸美的品牌大IP延续了近年来与艺术领域的 跨界合作，与中国先锋艺术家宋三土联名，把今年眼霜节的主题定为"一眼花花宇宙"。 丸美眼霜节现场 宋 三 土 是 目 前 国 内 商 业 领 域 ...

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

上世纪9 0年代初，大宝凭借一句"大宝，天天见！"的广告词，让大宝SOD蜜一炮而红。其中"SOD"，便是"超氧化物歧化酶"的简称。 也许至今很多消费者还不明白这几个字母的具体内涵，但大都对这种成分的养肤价值留下了印象。其实，这是一种存在于所有需氧生 物体内的天然抗氧化酶，是生物体有效清除活性氧的重要酶类之一。 技术演进让产品创新实现轮回。2 0 2 5年，美妆行业迎来一场"酶成分革命"。 国货"一哥"珀莱雅以"无花果蛋白酶萃"打造「精修瓶」，本土品牌羽素借" 3X智慧酶"重构焕肤体验。此外，毕生之研、C咖等新锐品 牌以"复合酶" "生物酶包裹"等创新技术跑步入场。 酶，这款蛰伏配方表数十年的老牌成分，为何从籍籍无名到如今逆袭成为"功效王牌"？这场技术狂欢究竟是营销泡沫，还是真能改写 美肤规则？ 在化妆品成分表中，酶类物质始终扮演着"无名英雄"的角色。多位业内资深研发人员告诉《FBe a u t y未来迹》，如果不是有意识去关 注，可能很难发现酶类物质早已渗透到护肤品的各个品类。 例如，珀莱雅在2 0 2 4年推出的「光学瓶」「红宝石精华3 . 0」中，都添加了SOD；丸美「小金针」面霜，则同时添加了辅酶Q1 ...

证券研究报告 2025 年 06 月 05 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3376.20 | 0.42 | | 深证成指 | 10144.58 | 0.87 | | 创业板指 | 2024.93 | 1.11 | | 科创 50 | 986.11 | 0.45 | | 北证 50 | 1438.73 | 1.10 | | 沪深 300 | 3868.74 | 0.43 | A 股市场概览 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | | (亿元) | 值(亿元) | PE | PB | | 上证指数 | 650328 | 507744 | 11.95 | 1.24 | | 深证成指 | 215963 | 182906 | 19.92 | 2.10 | | 创业板指 | 57287 | 45189 | 26.71 | 3.71 | | 科创 50 | 33966 | 22168 | 53.36 | 4.09 | | 北证 50 | ...

证券研究报告 | 行业深度报告 2025 年 05 月 21 日 Q1 分化延续，Q2 大促催化下关注头部国货机会 美妆个护 25Q1 总结及 Q2 展望 消费品/轻工纺服 行业指数 % 1m 6m 12m 绝对表现 9.2 10.9 7.9 相对表现 5.9 13.1 2.3 资料来源：公司数据、招商证券 -30 -20 -10 0 10 20 May/24 Sep/24 Dec/24 Apr/25 (%) 轻工纺服 沪深300 相关报告 1、《纺织服装 25Q1 总结及 Q2 展望 —品牌有望在 Q2 低基数情况下实现 稳健增长，制造短期承压》 2025-05-18 2、《中美日内瓦经贸会谈发布联合 声明点评—中美贸易摩擦预计将大 幅缓和，OEM 龙头有望估值修复》 2025-05-12 3、《纺织服装海外趋势跟踪（2025 年 4 月）—关税影响暂时减弱，关注 抗风险能力强的纺织制造龙头（更 新）》2025-04-16 化妆品板块 24 年及 25Q1 业绩分化延续，头部国货依旧凭借性价比、差异化产 品及定位、大单品战略及精细化线上运营等优势实现较好增长。个护板块 25Q1 表现较为亮眼，头部国货品牌凭 ...

Core Viewpoint - The domestic beauty brand market in China is experiencing strong growth, driven by increasing consumer recognition and confidence in local brands, as stated by the CEO of Marubi Biotechnology during the 2024 annual and Q1 2025 earnings presentation [1] Financial Performance - Marubi Biotechnology achieved a net profit attributable to shareholders of 342 million yuan for the fiscal year 2024, representing a year-on-year increase of 31.69%, while the net profit after deducting non-recurring gains and losses was 327 million yuan, up 73.86% year-on-year [1] - In Q1 2025, the company reported a net profit attributable to shareholders of 135 million yuan, a year-on-year increase of 22.07%, with the net profit after deducting non-recurring gains and losses at 134 million yuan, up 28.57% year-on-year [1] - The stock price of Marubi Biotechnology has increased by over 150% since September 2024, with a closing limit up on May 15 [1] Strategic Transformation - The company has undergone a strategic transformation from a traditional beauty enterprise to a biotechnology beauty company, as indicated by the renaming of its stock from "Marubi Co., Ltd." to "Marubi Biotechnology" in 2024 [2] - Marubi Biotechnology emphasizes the importance of biotechnology in its current and future operations, particularly in the development and industrial application of key technologies such as recombinant collagen protein [2] Research and Development - In 2024, Marubi Biotechnology was recognized as a "National Research Center for Recombinant Functional Protein Technology," conducting 20 specialized studies on recombinant functional proteins throughout the year [2] - The company has made significant advancements in the development of various types of recombinant collagen proteins and has filed for 10 invention patents related to key technologies [2] Industry Trends - The beauty industry is witnessing accelerated penetration of advanced technologies such as artificial intelligence, synthetic biology, and smart manufacturing, which are driving industry upgrades [3] - Consumer demand is becoming more diverse and personalized, leading to higher expectations for quality, efficacy, and added value in beauty products and services [3] Sales and Distribution Strategy - Marubi Biotechnology is pursuing a multi-channel collaborative development strategy, with its brands already present in duty-free stores and actively exploring other channel opportunities [3]

| ENVIRONMENTAL, SOCIAL AND | | | | | | --- | --- | --- | --- | --- | | GOVERNANCE REPORT | | | | | | Guangdong Marubi Biotechnology Co., Ltd. Table of Content | Steady Operation, | Environmental | | | | Forging | | | Protection, | | | Sustainable | | | Safeguarding the | | | Message from Chairman | | | | | | About Marubi | "Beauty" Power | 01 | Beauty of Ecology | 03 | | Enhancing Governance, Solidifying | | | 29 Embracing Green Values, Improving | 67 | | Recap of 2024 11 | Development Foundations | | Envi ...

核心观点 公司Q4 单季度营收10.17 亿元，同比增长47.64%，较24Q3 的+25.8%进一步加速，25Q1 营收+28%维持 在高位。盈利端24Q4对应扣非净利润率9.85%，全年扣非净利润率11%，+2.6pct，此次24Q4 验证大促 期的盈利稳定性已形成。2024 年线上营收25.41亿元/+35.77%，占比提升至85.61%，线上运营持续精 进。丸美小红笔眼霜3.0 全年线上GMV达5.33 亿元/+146%,小金针次抛精华2.0 线上GMV 达3.5 亿 元/+96%，大单品策略下毛利率提升显著。 2025 年公司进一步对小红笔及小金针系列进行扩充升级，推出小红笔水乳2.0，小金针超级面膜，并推 出大红盾进入防晒市场，恋火近期推出海岛限定系列拓宽人群，产品、渠道、品牌三维提升下今年增速 及业绩兑现值得期待。 事件 公司披露2024 年年报及2025 年一季报：Q4 实现营收10.17 亿元，+47.64%，归属股东净利润1.03 亿 元，+20.14%；扣非净利润1.00亿元，+225.88%。24 年全年营收29.70 亿元，+33.44%，归母净利润3.42 亿/+31.69%；扣非 ...